PBYIのチャート
PBYIの企業情報
| symbol | PBYI |
|---|---|
| 会社名 | Puma Biotechnology Inc. （プ―マ・バイオテクノロジ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 プーマ・バイオテクノロジー（Puma Biotechnology Inc.）は癌の治療用製品の開発・商品化に焦点を当てたバイオ医薬品会社である。同社は、PB272（ネラチニブ（経口））、PB272（ネラチニブ（静脈内））およびPB357を含む3つ以上の候補者に対する開発・商業化の権利をライセンス供与する。ネラチニブは、表皮成長因子受容体（EGFR）、HER1、HER2およびHER4を介したシグナル伝達をブロックする強力な不可逆的チロシンキナーゼ阻害剤（TKI）である。最初の焦点は、HER2陽性転移性乳癌患者の経口治療としてのネラチニブの開発にある。同社は、静脈内投与された薬剤としてのネラチニブの開発に焦点を当てている。ネラチニブの静脈内投与は、前臨床モデルにおけるネラチニブの暴露レベルをもたらす。製品候補であるPB357は、表皮成長因子受容体を介したシグナル伝達をブロックする不可逆的TKIである経口投与剤である。 プ―マ・バイオテクノロジ―は、開発段階のバイオ医薬品を手掛ける米国の会社。抗癌剤の開発に従事する。初期臨床試験を完了した薬やライセンス取得中の薬剤候補を中心に開発を行う。ライセンス取得済み薬剤候補は、進行乳癌患者・非小細胞肺癌患者向けPB272(経口)、進行癌患者向けPB272（静脈）、PB272のバックアップとしてPB357がある。 Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc. |
| 本社所在地 | 10880 Wilshire Boulevard Suite 2150 Los Angeles CA 90024 USA |
| 代表者氏名 | Alan H. Auerbach Alan H. Auerbach |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 424-248-6500 |
| 設立年月日 | 39173 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | ―年 |
| 従業員数 | 156人 |
| url | www.pumabiotechnology.com |
| nasdaq_url | https://www.nasdaq.com/symbol/pbyi |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -200.36000 |
| 終値（lastsale） | 45.34 |
| 時価総額（marketcap） | 1724052683.88 |
| 時価総額 | 時価総額（百万ドル） 1603.894 |
| 売上高 | 売上高（百万ドル） 144.96800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1589.651 |
| 当期純利益 | 当期純利益（百万ドル） -209.93800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Puma Biotechnology Inc revenues increased from $0K to $117.3M. Net loss decreased 54% to $68.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$4.08 to -$1.82. |
PBYIのテクニカル分析
PBYIのニュース
HER2 Inhibitors Global Market Report 2023 2023/02/08 16:58:00 GlobeNewswire
Major players in the HER2 inhibitors market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Boehringer-Ingelheim, Mylan and Biocon. The global her2 inhibitors market is expected to grow from $6.61 billion in 2021 to $7.26 billion in 2022 at a compound annual growth rate (CAGR) of 9.9%. Major players in the HER2 inhibitors market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Boehringer-Ingelheim, Mylan and Biocon. The global her2 inhibitors market is expected to grow from $6.61 billion in 2021 to $7.26 billion in 2022 at a compound annual growth rate (CAGR) of 9.9%.
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation 2023/02/01 13:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology''s drug neratinib (NERLYNX®) was added to the NCCN Clinical Practice Guidelines for treatment of breast cancer with a HER2 mutation.
Puma Biotechnology’s NERLYNX Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation 2023/02/01 13:30:00 Wallstreet:Online
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer were updated to include an addition involving neratinib (NERLYNX). The updated NCCN Practice Guidelines for Breast Cancer include neratinib combinations as category 2B potential targeted
Puma Biotechnology Releases Updated Corporate Presentation 2023/01/09 13:55:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released an updated corporate presentation that will be used in investor meetings in the coming weeks.
Puma (PBYI): Recent Rally Looks Overdone, Unsupported With Fundamentals 2022/12/27 13:30:00 Seeking Alpha
Puma Biotechnology recently bounced from its November lows, rallying from $2 to $5.16 in a matter of weeks. Click here to read my valuation analysis of PBYI stock.
Investing in Puma Biotechnology Inc. (PBYI) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/11/22 15:24:00 US Post News
Puma Biotechnology Inc. (NASDAQ:PBYI) closed Monday at $4.50 per share, up from $3.75 a day earlier. While Puma Biotechnology Inc. has overperformed by 20.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PBYI rose by 31.58%, with highs and lows ranging from $4.07 to $1.60, whereas […]
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday 2022/11/22 08:49:19 Benzinga
Gainers Imago BioSciences, Inc. (NASDAQ: IMGO ) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. NeuroOne Medical Technologies Corporation (NASDAQ: NMTC ) jumped 44.5% to close at $1.20. NeuroOne, last month, received FDA 510(k) clearance to market its Evo sEEG System for less than 30 day use. OncoSec Medical Incorporated (NASDAQ: ONCS ) gained 42.2% to close at $4.85. OncoSec Medical recently announced early clinical data from an investigator-sponsored trial of TAVO in combination with Bristol-Myers Squibb’s intravenous Opdivo (nivolumab). Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO ) surged 40.3% to close at $2.47. NWTN Inc. (NASDAQ: NWTN ) jumped 38.8% to close at $7.05. SeaStar Medical Holding Corporation (NASDAQ: ICU ) shares jumped 33.6% to close at $5.25. Sotera Health Company (NASDAQ: SHC ) gained 32.9% to close at $8.00. Barclays, last week, downgraded Sotera Health from Equal-Weight to Underweight and lowered the price target from $7 to $6.
Why Puma Biotechnology''s Shares Jumped 20% on Monday 2022/11/21 22:25:39 The Motley Fool
It may have benefited from positive news about another company''s drug candidate.
Puma Biotechnology Inc. (NASDAQ: PBYI) Stock Jumped 74.42% Over A Month – Are There Any Chances Of Growth? 2022/11/19 18:00:00 Marketing Sentinel
During the last session, Puma Biotechnology Inc. (NASDAQ:PBYI)’s traded shares were 0.44 million, with the beta value of the company hitting 0.66. At the end of the trading day, the stock’s price was $3.75, reflecting an intraday gain of 5.93% or $0.21. The 52-week high for the PBYI share is $4.07, that puts it down … Puma Biotechnology Inc. (NASDAQ: PBYI) Stock Jumped 74.42% Over A Month – Are There Any Chances Of Growth? Read More »
S&P 500 Down 1%; Crude Oil Drops Sharply 2022/11/17 17:07:12 Benzinga
U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday. The Dow traded down 0.53% to 33,377.30 while the NASDAQ fell 0.85% to 11,088.75. The S&P 500 also fell, dropping, 0.96% to 3,920.64. Also check this: Nasdaq Drops Sharply, But Market Volatility Decreases Leading and Lagging Sectors Health care shares fell by just 0.3% on Thursday. Leading the sector was strength from Ardelyx, Inc. (NASDAQ: ARDX ) and Puma Biotechnology, Inc. (NASDAQ: PBYI ). In trading on Thursday, utilities dipped by 2%. Top Headline US jobless claims dropped by 4,000 to 222,000 on the week ending November 12th, compared to market estimates of 225,000. Equities Trading UP Bath & Body Works, Inc. (NYSE: BBWI ) shares shot up 20% to $37.23 after the company reported better-than-expected Q3 results. Shares of Ardelyx, Inc. (NASDAQ: ARDX ) got a boost, shooting 37% to $1.6750 after the company announced the FDA Advisory Committee voted 9-to-4 that the benefits of XPHOZAH outweigh its risks for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results 2022/02/16 21:15:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 pm PST on March 3 to review its fourth quarter and full year 2021 financial results.
Puma Biotechnology reports inducement awards under Nasdaq listing rule 2022/02/03 22:36:10 Seeking Alpha
Puma Biotechnology (PBYI) has announced that the Compensation Committee of Pumas Board approved the grant of inducement restricted stock unit awards covering an aggregate of 24,375
Puma Biotech''s Nerlynx Included In NCCN Guidelines For Breast Cancer 2022/01/13 11:25:11 Benzinga
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two essential changes for Puma Biotechnology Inc (NASDAQ: PBYI ) Nerlynx (neratinib). The first update added Nerlynx to the body of the guidelines for treating adjuvant HER2-positive Breast Cancer, with Full story available on Benzinga.com
Puma Biotechnology, Marin Software lead aftermarket gainers; Vaxcyte among losers 2022/01/12 22:14:34 Seeking Alpha
Gainers: Puma Biotechnology PBYI +16%, Marin Software (MRIN) +9%, Midland States Bancorp (MSBI) +6%, IDEAYA Biosciences (IDYA) +3%, Ironwood Pharmaceuticals (IRWD) +3%.Losers:…
Puma Biotechnology says its breast cancer therapy included in two key NCCN updates 2022/01/12 21:28:35 Seeking Alpha
Micro-cap stock, Puma Biotechnology (PBYI) has added 12.6% in the post-market after announcing that two new updates involving its FDA-approved therapy neratinib (NERLYNX) were added to